The gain of somatic copy number alteration in both primary and lymph node metastases predict poor prognosis of non-samll cell lung cancer.

Abstract

e20511 Background: Lung cancer is the leading cause of cancer-related mortality among the world, and distant metastases is still the main cause of poor prognosis and cancer-related deaths. Lymph nodes nearby primary tumor is the most commonly metastases. More than 90% NSCLC patients were diagnosed at II or higher stage. Although more and more prognosis molecular biomarkers have been identified, it’s still hard to completely understand the metastases mechanism of NSCLC. Here we work on evaluation whether molecular divergence or common mutational characters in matched primary and lymph node metastases of NSCLC could predict patient’s prognosis. Methods: Within MSKCC(MSK-IMPACT-2017) datasets, 12 matched primary and lymph node metastatic samples were gotten. Molecular divergence and similarity were analyzed between matched samples, including SNVs, fusion mutations, CNA, TMB, signature, concordance between primary and metastatic lymph nodes and relate it to patient’s overall survival. Results: Cox survival analysis results proved that the gain of CNA in both primary and lymph node metastases would be a poor prognosis biomarker for NSCLC. 3/3 NSCLC patients with CNA in both primary and metastases occurred death within 10 months, median OS was 7.76 month. Only 1/9 of the others occurred death at 14 months, other NSCLC patients did not reach the end point of this study. HR for OS with CNA in both matched samples versus the others was 0.07 (95% CI 0.0067-0.67), log-rank p value was 0.0028. Conclusions: The gain of CNA in both primary and lymph node metastases could be a poor prognosis predictor for NSCLC patients.